5F-AB-PINACA
A fluorinated indazole-3-carboxamide, full agonist at CB1 and CB2, convulsant in mice; a narcotic in France.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₈H₂₅FN₄O₂
CAS 1800101-60-3
- Family
- Synthetic CB receptor agonistNew psychoactive substance
- Molar mass
- 348.42 g/mol
Updated on
In plain terms
5F-AB-PINACA has nothing to do with hemp: it is a molecule made in the laboratory. It acts on the same receptors as THC. In mice it causes convulsions; in Japan, road accidents with impaired consciousness were reported with five synthetic cannabinoids including this one. In France it is classed as a narcotic.
Receptors and activity
Target network
- Activates
The lower the cited value, the closer the target sits to 5F-AB-PINACA: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 5F-AB-PINACA.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Agonistno measured value cited
- CB2Agonistno measured value cited
Pharmacology
5F-AB-PINACA is a synthetic cannabinoid agonist of the indazole-3-carboxamide family, the 5-fluorinated analogue of AB-PINACA. Banister et al. (2015) synthesised and tested it with other compounds (AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-ADB-PINACA…): all act as high-potency agonists at CB1 (EC50 of 0.24 to 21 nM) and CB2 (EC50 of 0.88 to 15 nM) receptors. Whereas Δ9-THC is a partial agonist, 5F-AB-PINACA behaves as a full agonist with high intrinsic efficacy: in mice, Wilson et al. (2019) observe convulsions attenuated by a CB1 antagonist but not by diazepam, which suggests that benzodiazepines may not be enough to control them. Kaneko (2017) links road accidents in Japan to five synthetic cannabinoids, including 5F-AB-PINACA, with impaired consciousness, anterograde amnesia, catalepsy, tachycardia and vomiting. No published human pharmacokinetics were found in the sources consulted.
Key sources.
- Banister · ACS Chem Neurosci 2015 (new tab)PMID 26134475
- Wohlfarth · AAPS J 2015 (new tab)PMID 25721194
- Wilson · J Pharmacol Exp Ther 2019 (new tab)PMID 30420360
- Gamage · J Pharmacol Exp Ther 2019 (new tab)PMID 30552295
- Wilson · Drug Alcohol Depend 2022 (new tab)PMID 35643039
- Kaneko · Forensic Toxicol 2017 (new tab)PMID 28706566
- Longworth · Forensic Toxicol 2016 (new tab)PMID 27547266
History
- Source
- Clandestine synthesis, outside any pharmaceutical channel. No natural occurrence: the molecule is absent from cannabis and from any other plant. It has been found in smoking products in Japan (Kaneko 2017).
Origin
Laboratory synthesis
No biosynthetic pathway: an entirely synthetic molecule, with no plant precursor. The skeleton combines an indazole-3-carboxamide nucleus, an N1-(5-fluoropentyl) chain and a primary L-valinamide head.
Legal framework
- European Union
No Union control measure names it; it is not in the Schedules of the 1971 Convention (INCB Green List, 35th ed., 2024)
- France
A narcotic: named in Annex IV of the order of 22 February 1990 (ANSM consolidated list of 26/06/2026), among the examples of a generic family of indazole carboxamides
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
Synthetic CB receptor agonist › New psychoactive substance
- Class
indazole-3-carboxamide
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Banister · ACS Chem Neurosci 2015 (new tab)PMID 26134475
- Wohlfarth · AAPS J 2015 (new tab)PMID 25721194
- Wilson · J Pharmacol Exp Ther 2019 (new tab)PMID 30420360
- Gamage · J Pharmacol Exp Ther 2019 (new tab)PMID 30552295
- Wilson · Drug Alcohol Depend 2022 (new tab)PMID 35643039
- Kaneko · Forensic Toxicol 2017 (new tab)PMID 28706566
- Longworth · Forensic Toxicol 2016 (new tab)PMID 27547266
Identifiers
Names
- IUPAC name
- N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-(5-fluoropentyl)indazole-3-carboxamide
- Other names
- 5-fluoro-AB-PINACA
Identifiers
- Formula
- C₁₈H₂₅FN₄O₂
- CAS
- 1800101-60-3
- PubChem CID
- 91936927(new tab)
- InChIKey
- WCBYXIBEPFZUBG-HNNXBMFYSA-N
- SMILES
- CC(C)
[C@@H] (C(= O) N) NC(= O) C1= NN(C2= CC= CC= C21) CCCCCF
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.